Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Thioredoxin domain-containing protein 12 (TXNDC12) is an enzyme of the thioredoxin superfamily localized in the endoplasmic reticulum, functioning primarily as a protein-disulfide isomerase[1][5]. It catalyzes the formation and rearrangement of disulfide bonds during protein folding, contributing to the proper maturation of secretory and membrane proteins, and plays a protective role against endoplasmic reticulum stress[1][5]. TXNDC12 is upregulated in multiple cancers, including hepatocellular carcinoma and glioma, where it promotes tumor metastasis and epithelial–mesenchymal transition (EMT) through activation and nuclear translocation of β-catenin and upregulation of ZEB1[1][3]. Its high expression correlates with poor clinical outcomes and increased tumor aggressiveness, supporting its potential as a therapeutic target and prognostic biomarker in cancer[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Thioredoxin domain-containing protein 12 (TXNDC12).